This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...

Just as Adverum Biotechnologies' cash reserves were running dry, Eli Lilly has swooped in | Just as Adverum’s cash reserves ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Despite the recent attention to the potential of developing and using gene therapy to treat several diseases, the therapy was ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

scientists developed a customized gene therapy consisting of a guide and an mRNA that carried instructions for a base editor ...

Q3 2025 Earnings Call October 28, 2025 8:30 AM EDTCompany ParticipantsJacob JohnsonOlivier Loeillot - President, ...

Presenters at the AAO 2025 meeting outlined a future for retinal care that reduces patient burden by reconsidering treatment delivery methods.

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today ...

-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- JCR Pharmaceuticals Co., Ltd. (TSE 4552; ...